EHA 2022 | Results from a subgroup analysis of ZUMA-3 and the efficacy of brexu-cel in R/R B-ALL
In this video, Ryan Cassaday, MD, University of Washington, Seattle, WA, discusses some results from a subgroup analysis of the ZUMA-3 trial (NCT02614066), which investigated the safety and efficacy of brexucabtagene autoleucel (brexu-cel) in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), and led to the approval of this agent for this patient population. Dr Cassaday first explains the purpose of this subgroup analysis and then goes on to discuss the main results and overall efficacy of brexu-cel for the treatment of R/R B-ALL. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Research funding from Amgen, Kite/Gilead, Merck, Pfizer, Servier, and Vanda Pharmaceuticals; consulting/honoraria from Amgen, Kite/Gilead, and Pfizer; and spouse is employed by and owns stock in Seagen.
